Shandong Lukang Pharmaceutical Co., Ltd.SSE: 600789

Announcement on Convening the 2024 Annual Performance Briefing

Apr 12, 2025 · Issued by Shandong Lukang Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 12, 2025

On 6ix: 6ix.com/news/announcement-on-convening-the-2024-annual-performance-briefing-112

Announcement on Convening the 2024 Annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Shandong Lukang Pharmaceutical Co., Ltd. on 6ix

Earlier from Shandong Lukang Pharmaceutical

Announcement on Reception of Investor ResearchApr 3, 2025
Announcement on Renewing Engagement of Accounting FirmMar 22, 2025
Announcement on Obtaining Drug Registration Certificate by the Holding SubsidiaryFeb 11, 2025
Announcement on Expected Increase in Annual Performance for 2024Jan 27, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025Jan 17, 2025

Later from Shandong Lukang Pharmaceutical

Announcement on Acceptance of Application for Issuance of A Shares to Specific Objects by Shanghai Stock ExchangeApr 19, 2025
Announcement on Resolution of the 7th (Extraordinary) Meeting of the 11th Board of DirectorsApr 30, 2025
Announcement on Receiving Approval Notice of Marketing Application for Celecoxib as Chemical Active Pharmaceutical IngredientMay 9, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Shandong JurisdictionMay 13, 2025
Reply to SSE Inquiry Letter on Ex Post Audit of the Company's 2024 Annual ReportMay 15, 2025

All Shandong Lukang Pharmaceutical news releases

Follow Shandong Lukang Pharmaceutical into a list and get an email when it puts out news.

Follow Shandong Lukang Pharmaceutical